Drug discovery traditionally is a long and expensive process. It requires huge financial investment and can

possibly take more than a decade to develop a single drug. In this paper, It has been explored how generative AI

is changing this process. By using advanced models, generative AI can design new drug molecules, predict their

properties, improve efficiency by reducing both time and cost required for research to get precise and accurate

data. These models can generate drug candidates with better binding affinity and drug like properties, making

the selection process more reliable. It is also being used across different stages of drug discovery, from

identifying targets to monitoring drug safety. Although generative AI has great potential to transform drug

discovery by making it faster, more efficient and accurate, there are still some challenges like the need for high

quality data, lack of model transparency, regulatory concerns and more real world testing and comparison. These

improvements are still needed for its full adoption.

logistical challenges.

Traditionally, drug discovery has relied on methods such as high-throughput screening, iterative medicinal

chemistry, and extensive experimental validation. While these approaches are effective, they are often time-

consuming and limited in their ability to explore the vast chemical space or accurately predict complex biological

interactions.

In recent years, generative AI has emerged as a transformative technology in this field. By leveraging advanced

computational models, particularly deep learning and diffusion-based techniques, generative AI can design and

optimize novel molecular structures more efficiently. It enables researchers to automate molecular generation,

improve drug-like properties, and integrate diverse biological data for better decision-making. As a result,

generative AI holds great potential to accelerate drug discovery, enhance candidate selection accuracy, and

Similarly, the application of denoising diffusion probabilistic models (DDPMs) to molecular dynamics (MD)

simulations reduced computational costs to one third of traditional umbrella sampling approaches, making high-

throughput screening feasible for membrane partitioning studies (Obi et al., 2024).

B. Accuracy: Better Candidate Selection

Generative AI does not just save time, it also produces better candidates. IDOLpro generated ligands with

binding affinities 10–20% higher than the next best method, and remarkably, it was the first approach to generate

molecules that outperformed experimentally observed ligands in benchmark binding assays (Kadan et al., 2025).

The DDPM models also showed strong accuracy, correctly predicting membrane interaction parameters and

ligand orientations for a range of FDA approved drugs (Obi et al., 2024).

In a more disease-specific application, the CRISPR-TICA.ai pipeline combined functional genomics data with

C. Challenges and Limitations

Despite the promising results, there are real challenges that need to be addressed before generative AI can be

fully trusted in drug discovery settings. Data quality is a big concern, if the training data is biased or incomplete,

the models can produce misleading results (Abbas et al., 2024). Model interpretability is another issue: many

generative AI models are essentially black boxes, which is a problem when regulators and clinicians need to

understand why a particular candidate was selected (Abbas et al., 2024) ( Bordukova et al., 2023).

Scalability and generalizability are also open questions. Most studies have demonstrated results for specific

targets or disease areas, and it is not always clear how well these approaches would transfer to other contexts.

The field also lacks the kind of systematic, benchmarking studies that would make it easier to compare different

generative AI approaches against each other and against traditional methods (Zhang et al., 2024) ( Lai et al.,

.

Ethical and Regulatory Frameworks: As generative AI becomes more pervasive, robust frameworks are

Taken together, the evidence strongly suggests that generative AI is bringing meaningful changes to drug

discovery, particularly in the early stages such as molecular design and candidate prioritization. Its ability to

rapidly generate and evaluate novel compounds, while simultaneously optimizing multiple properties offers a

clear advantage over traditional methods and opens up new possibilities for innovation.

Another important aspect is the versatility of generative AI. Beyond discovering new molecules, it is increasingly

being used to model membrane interactions, predict adverse drug reactions, and simulate clinical trials. This

Looking ahead, future research should focus on systematic comparisons between generative AI and traditional

approaches across all stages of drug discovery. Improving model transparency will be essential for building trust

among regulators and clinicians. Additionally, deeper integration with experimental workflows and the

development of robust ethical and regulatory frameworks will be critical for long term success.

In conclusion, generative AI is not a complete replacement for existing methods, but it represents a powerful

and transformative advancement in drug discovery. With continued improvement, validation, and responsible

implementation, it has the potential to make drug development faster, more cost-effective, and more accurate

ultimately benefiting patients worldwide.